Catalyst Event
Novartis AG (NVS) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/30/2026, 12:00:00 AM
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
Korean Translation
2026-06-30 심혈관 후보물질 펠라카르센의 3상 Lp(a)HORIZON 연구 결과가 발표될 예정임. 주요 임상 결과에 따른 5% 이상의 주가 변동이 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM
ICON Public Limited Company (ICLR) · Earnings Release
High importance is estimated due to the preceding accounting investigation and potential for significant market volatility. Delayed fourth-quarter and full-year 2025 earnings results scheduled.
4/30/2026, 12:00:00 AM